Despite not having a positive outcome, safety profiles for Keytruda and Lynparza were consistent with previous findings.
Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer